

## Grifols is included on Euronext Vigeo indices and recognized once again as one of the world's most sustainable companies

- *For the first time ever, Grifols has been included on the Euronext Vigeo Europe 120 and Euronext Vigeo Eurozone 120 indices based on the evaluation by Vigeo Eiris, the prestigious rating agency that assesses the performance of the 120 most sustainable listed companies in Europe*
- *As of this year, Grifols also forms part of the Dow Jones Sustainability Index (DJSI) Europe and since 2018, the FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex indices*
- *In addition, Grifols improves its Carbon Disclosure Project (CDP) rating and is positioned as one of the leading companies against climate change*

**Barcelona, December 9, 2020.**- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare leader in the production of plasma-derived medicines with a proven track record of more than 100 years dedicated to enhancing the health and well-being of people worldwide, has been recognized once again as one of the world's most sustainable companies. For the first time in its history, the company has been included on the Euronext Vigeo Europe 120 and Euronext Vigeo Eurozone 120 indices, ranking among the top three European companies in its sector.

The Euronext Vigeo index is a twice-yearly ranking of the 120 most sustainable listed companies based on the assessment by Vigeo Eiris, a rating agency that evaluates organizations' performance according to environmental, social and governance (ESG) criteria.

Grifols also achieved a higher Carbon Disclosure Project (CDP) rating, the world's leading environmental information platform that annually assesses corporate strategies and performance in relation to climate change. The company has increased its qualification in recent years, reaching an "A-" management rating in 2020.

For Raimon Grifols and Víctor Grifols Deu, co-CEOs of Grifols, *"After the company's inclusion on the Dow Jones Sustainability Index, this new recognition by Vigeo Eiris and the improvement in the Carbon Disclosure Project rating are two milestones that reaffirm our solid commitment to sustainability, which has guided Grifols since its creation more than 100 years ago.*

*COVID-19 has generated numerous challenges. At Grifols, we believe that now more than ever, we need to provide transparency on social and environmental issues at all organizational levels, supported by a robust corporate governance structure. This objective is key as the*

*company continues to build on its commitment to enhance the health and well-being of donors, patients and society.*

*The distinctions awarded underline our transparency and reporting efforts in recent years and encourages us to continue working in the same direction.”*

A broad range of financial market players consider ESG indices when making their investment decisions.

Grifols has been listed on the Dow Jones Sustainability Index (DJSI) Europe since November 2020 and on the sustainability indices FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex since 2018.

---

## **Investor contact:**

### **Investor Relations**

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Phone number: +34 93 571 02 21

## **Media contacts:**

Raquel Lumbreras [Raquel\\_lumbreras@duomocomunicacion.com](mailto:Raquel_lumbreras@duomocomunicacion.com)

Borja Gómez [Borja\\_gomez@duomocomunicacion.com](mailto:Borja_gomez@duomocomunicacion.com)

Duomo Comunicación – **Grifols PR office**

Tel. +34 91 311 92 89 - 91 311 92 90

---

## **About Grifols**

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [www.grifols.com](http://www.grifols.com)

---

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.